Skip to main content
Clinical Trials/EUCTR2006-005386-19-BE
EUCTR2006-005386-19-BE
Active, not recruiting
Phase 1

Cytokines and inflammatory proteins gene expression study in synovial biopsies from rheumatoid arthritis patients refractory to anti-TNF therapy treated with Rituximab - Anti TNF resistant RA / RTX / mini

Cliniques Universitaires Saint-Luc0 sites20 target enrollmentNovember 3, 2006

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Rheumatoid arthritis refractory to TNF blockers patients
Sponsor
Cliniques Universitaires Saint-Luc
Enrollment
20
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 3, 2006
End Date
December 24, 2008
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of RA (according to ACR criteria)
  • Active RA defined by a DAS28\-CRP score \> 5\.1 or \>3\.2 with a swollen joint count \= 8
  • Presence of knee arthralgia or synovitis
  • Failure to at least one TNF blocker (Remicade, Enbrel, Humira)
  • Stable therapy with MTX, corticosteroïds or NSAIDs
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • Previous Rituximab treatment
  • Exclusion for general safety (history of severe allergic reaction, sepsis, malignancy within 5 years, pregnancy, severe heart failure)
  • Excluded Concomitant Medications :
  • Concurrent treatment with other DMARDs than MTX or any anti\-TNF and biological therapies. Enbrel, Remicade and Humira should be respectively stopped 4, 8 and 8 weeks before inclusion.

Outcomes

Primary Outcomes

Not specified

Similar Trials